Kane Biotech Acquires FB Dermatology To Enhance Wound And Skin Care Portfolio

Kane Biotech Inc. has announced a binding term sheet to acquire all shares of FB Dermatology S.R.L., an Italian company with operations in Italy and Australia and product sales across Europe, Australia, and New Zealand.

Marc Edwards, President and CEO of Kane Biotech, stated, “This transaction is a powerful catalyst for Kane Biotech’s growth.FB Dermatology’s Fluorescent Light Energy Technology, or FLETECH, offers a proven, patented, and fully commercialised portfolio with impactful wound care and dermatology applications. 

He further added, “With this acquisition, we are positioning Kane Biotech as one of the frontrunners in delivering one of the best and most innovative solutions in these fields, backed by an advanced lineup of products. I’m enthusiastic about the future potential of our combined organisation, especially as this transaction significantly enhances our commercial capabilities, setting the stage for accelerated growth and impact in the market.” 

He also commented, “We’re thrilled to move this transaction forward with minimal dilution and an initial minimal cash component. This approach aligns with our commitment to maximising shareholder value and preserving our financial strength, and we believe it’s a win for our investors,”

FB Dermatology’s product lineup includes:

• LumiHeal®, a treatment for chronic wounds and surgical scar reduction, approved by the EU (CE Mark) and FDA. LumiHeal works on the principles of  Fluorescence Biomodulation to stimulate skin healing at the cellular level across inflammation, proliferation, and remodelling phases.

  
  

• Kleresca® promotes natural skin repair and is used to rejuvenate and treat acne and rosacea. It also holds a European Union MDR CE Mark. 

  
  

• Lumixa® is a product that relies on photobiomodulation to trigger biological regeneration processes within the skin.

  
  

Kane Biotech expects multiple benefits from this acquisition, including:

- Accelerating the rollout of its revyve™ Antimicrobial Wound Gel across international markets such as Australia and New Zealand, leveraging FB Dermatology’s local teams. Kane Biotech’s ISO 13485:2016 certification under MDSAP aligns with Australian regulatory standards, while its FDA 510(k) clearance will streamline approval in Australia and New Zealand.

- Expanding Kane Biotech’s DermaKB® product line through FB Dermatology’s sales channels in Europe, Australia, and New Zealand.

- Coordinating the launch of Lumixa® in the U.S. and Canada for wound care and dermatology, in conjunction with Kane Biotech’s coactiv+™ technology, including the revyve™ line.

- Introducing FB Dermatology’s LumiHeal® technology for surgical scar treatment, alongside Kane Biotech’s coactiv+™ Antimicrobial Surgical Gel, in the U.S. market.

Dr Francesco Bellini, the majority shareholder of FB Dermatology, said, “Kane Biotech’s vision and expertise align closely with our goals, and we are fully committed to supporting their growth and innovation as long-term shareholders. We believe Kane Biotech is well-positioned to unlock significant value, and we look forward to partnering with them on this exciting journey to make a lasting impact in the industry.”